Collegium Pharmaceutical, Inc.
COLL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $209 | $188 | $178 | $182 |
| % Growth | 11.4% | 5.8% | -2.3% | – |
| Cost of Goods Sold | $80 | $80 | $80 | $84 |
| Gross Profit | $129 | $108 | $97 | $98 |
| % Margin | 61.7% | 57.7% | 54.8% | 54% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $66 | $74 | $76 | $63 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$1 | -$3 |
| Operating Expenses | $66 | $73 | $76 | $60 |
| Operating Income | $64 | $35 | $22 | $38 |
| % Margin | 30.4% | 18.7% | 12.2% | 20.9% |
| Other Income/Exp. Net | -$20 | -$18 | -$19 | -$21 |
| Pre-Tax Income | $43 | $17 | $3 | $17 |
| Tax Expense | $12 | $5 | $1 | $5 |
| Net Income | $32 | $12 | $2 | $13 |
| % Margin | 15% | 6.4% | 1.4% | 6.9% |
| EPS | 1 | 0.38 | 0.076 | 0.39 |
| % Growth | 163.2% | 400% | -80.5% | – |
| EPS Diluted | 0.84 | 0.34 | 0.074 | 0.35 |
| Weighted Avg Shares Out | 32 | 32 | 32 | 32 |
| Weighted Avg Shares Out Dil | 39 | 39 | 33 | 40 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $2 | $2 | $2 |
| Interest Expense | $22 | $20 | $21 | $23 |
| Depreciation & Amortization | $57 | $57 | $57 | $57 |
| EBITDA | $122 | $94 | $80 | $96 |
| % Margin | 58.1% | 50.1% | 45.3% | 53% |